Tubulointerstitial Nephritis in ANCA-Associated Vasculitis as a Rare Adverse Effect of Adalimumab: A Case Report.

IF 0.7 Q4 PHARMACOLOGY & PHARMACY Current drug safety Pub Date : 2025-03-26 DOI:10.2174/0115748863362460250220172535

Myriam Ayari, Maha Mtir, Ikram Mami, Lamia Rais, Sarah Ben Azouz, Hedi Douggui, Taieb Jomni

{"title":"Tubulointerstitial Nephritis in ANCA-Associated Vasculitis as a Rare Adverse Effect of Adalimumab: A Case Report.","authors":"Myriam Ayari, Maha Mtir, Ikram Mami, Lamia Rais, Sarah Ben Azouz, Hedi Douggui, Taieb Jomni","doi":"10.2174/0115748863362460250220172535","DOIUrl":null,"url":null,"abstract":"Background: Patients with inflammatory disease treated with biological agents are at an increased risk of developing various adverse effects. However, little is known about the risk of nephrotoxicity, such as induced tubulointerstitial nephritis and immune-mediated inflammatory diseases involving the interstitium and renal tubule.Case report: We herein describe a case of biopsy-proven tubulointerstitial nephritis, induced by PR3-ANCA-associated vasculitis following adalimumab therapy in a patient with Crohn's disease and ankylosing spondylitis. We review the current evidence on adalimumab-induced nephrotoxicity and the potential underlying mechanisms.Conclusion: Monitoring of renal function is strongly recommended in all patients treated with adalimumab. Early diagnosis of drug-induced tubulointerstitial nephritis due to vasculitis and immediate withdrawal of the offending drug are key to renal recovery and prevention from irreversible serious organ damage.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863362460250220172535","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Patients with inflammatory disease treated with biological agents are at an increased risk of developing various adverse effects. However, little is known about the risk of nephrotoxicity, such as induced tubulointerstitial nephritis and immune-mediated inflammatory diseases involving the interstitium and renal tubule.

Case report: We herein describe a case of biopsy-proven tubulointerstitial nephritis, induced by PR3-ANCA-associated vasculitis following adalimumab therapy in a patient with Crohn's disease and ankylosing spondylitis. We review the current evidence on adalimumab-induced nephrotoxicity and the potential underlying mechanisms.

Conclusion: Monitoring of renal function is strongly recommended in all patients treated with adalimumab. Early diagnosis of drug-induced tubulointerstitial nephritis due to vasculitis and immediate withdrawal of the offending drug are key to renal recovery and prevention from irreversible serious organ damage.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

小管间质性肾炎合并anca相关性血管炎是阿达木单抗罕见的不良反应：1例报告。

背景：使用生物制剂治疗炎症性疾病的患者发生各种不良反应的风险增加。然而，对肾毒性的风险知之甚少，例如诱导的小管间质性肾炎和涉及间质和肾小管的免疫介导的炎症性疾病。病例报告：我们在此描述一例活检证实的小管间质性肾炎，在阿达木单抗治疗后由pr3 - anca相关血管炎诱导的克罗恩病和强直性脊柱炎患者。我们回顾了目前关于阿达木单抗引起的肾毒性及其潜在机制的证据。结论：强烈建议所有接受阿达木单抗治疗的患者监测肾功能。早期诊断由血管炎引起的药物性小管间质性肾炎并立即停用药物是恢复肾脏和防止不可逆的严重器官损害的关键。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current drug safety PHARMACOLOGY & PHARMACY-

CiteScore

2.10

自引率

0.00%

发文量

112

期刊介绍： Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.